Peterson Financial Group Inc. Buys Shares of 30 Eli Lilly and Company (NYSE:LLY)

Peterson Financial Group Inc. purchased a new position in Eli Lilly and Company (NYSE:LLY) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 30 shares of the company’s stock, valued at approximately $27,000.

Several other hedge funds also recently made changes to their positions in the stock. China Universal Asset Management Co. Ltd. increased its position in shares of Eli Lilly and Company by 19.6% during the first quarter. China Universal Asset Management Co. Ltd. now owns 9,897 shares of the company’s stock valued at $7,699,000 after buying an additional 1,620 shares during the period. Acadian Asset Management LLC increased its holdings in Eli Lilly and Company by 6.6% during the 1st quarter. Acadian Asset Management LLC now owns 36,897 shares of the company’s stock worth $28,699,000 after acquiring an additional 2,289 shares during the period. Edgestream Partners L.P. lifted its stake in Eli Lilly and Company by 13.8% in the 1st quarter. Edgestream Partners L.P. now owns 5,348 shares of the company’s stock worth $4,161,000 after purchasing an additional 649 shares in the last quarter. Covestor Ltd boosted its holdings in Eli Lilly and Company by 6.5% in the 1st quarter. Covestor Ltd now owns 296 shares of the company’s stock valued at $230,000 after purchasing an additional 18 shares during the period. Finally, Alley Investment Management Company LLC boosted its holdings in Eli Lilly and Company by 0.4% in the 1st quarter. Alley Investment Management Company LLC now owns 10,623 shares of the company’s stock valued at $8,264,000 after purchasing an additional 38 shares during the period. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Eli Lilly and Company Stock Down 4.9 %

LLY opened at $746.20 on Friday. Eli Lilly and Company has a 12 month low of $561.65 and a 12 month high of $972.53. The company has a current ratio of 1.27, a quick ratio of 0.97 and a debt-to-equity ratio of 2.03. The business’s 50-day moving average price is $882.65 and its 200-day moving average price is $870.38. The company has a market cap of $708.38 billion, a P/E ratio of 80.67, a P/E/G ratio of 2.82 and a beta of 0.43.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Wednesday, October 30th. The company reported $1.18 EPS for the quarter, missing analysts’ consensus estimates of $1.52 by ($0.34). Eli Lilly and Company had a return on equity of 71.08% and a net margin of 20.48%. The company had revenue of $11.44 billion during the quarter, compared to analysts’ expectations of $12.09 billion. During the same period last year, the firm earned $0.10 earnings per share. Eli Lilly and Company’s revenue for the quarter was up 20.4% on a year-over-year basis. On average, equities analysts expect that Eli Lilly and Company will post 13.21 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 10th. Investors of record on Friday, November 15th will be issued a dividend of $1.30 per share. The ex-dividend date of this dividend is Friday, November 15th. This represents a $5.20 dividend on an annualized basis and a yield of 0.70%. Eli Lilly and Company’s dividend payout ratio is currently 56.22%.

Insider Buying and Selling at Eli Lilly and Company

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 900 shares of the company’s stock in a transaction that occurred on Friday, November 8th. The stock was sold at an average price of $803.38, for a total transaction of $723,042.00. Following the completion of the transaction, the chief accounting officer now owns 5,480 shares of the company’s stock, valued at $4,402,522.40. This represents a 14.11 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 0.13% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on the company. Wolfe Research started coverage on Eli Lilly and Company in a research report on Friday. They issued an “outperform” rating and a $1,000.00 price objective on the stock. Berenberg Bank raised their price target on Eli Lilly and Company from $1,000.00 to $1,050.00 and gave the company a “buy” rating in a report on Wednesday, August 14th. Wells Fargo & Company boosted their price objective on Eli Lilly and Company from $875.00 to $1,000.00 and gave the stock an “overweight” rating in a report on Friday, August 9th. Guggenheim raised their target price on shares of Eli Lilly and Company from $884.00 to $1,030.00 and gave the company a “buy” rating in a research note on Friday, August 16th. Finally, Deutsche Bank Aktiengesellschaft lowered their price objective on shares of Eli Lilly and Company from $1,025.00 to $1,015.00 and set a “buy” rating on the stock in a research report on Monday, November 4th. Four investment analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $1,007.94.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.